Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

33

Revenue 2017

Humalog

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Humalog was produced by Lilly.

Lilly joins new Medicare scheme to reduce insulin prices

Lilly joins new Medicare scheme to reduce insulin prices

Lilly has faced particularly strong criticism, after its widely-used Humalog insulin rose from $34 to $234 per vial between 2001 and 2015.

Lilly will aim for one $1bn-$5bn deal per quarter in 2020

Lilly will aim for one $1bn-$5bn deal per quarter in 2020 Lilly needs to refresh its pipeline as it continues to suffer from a decline across its older, established brands – including in its diabetes franchise, where its Humalog insulin is facing generic ... The company recently announced its will launch lower

Lilly extends range of cut-price insulins in the US

Lilly extends range of cut-price insulins in the US Cheaper, authorised generic versions of Lilly’s Humalog Junior KwikPen and Humalog Mix75/25 products – priced at $265.20 for a pack of five which is another 50% reduction on the ... Humalog pay less than $100 for their monthly prescription at retail

Novo follows Sanofi, Lilly with insulin price cut in US

Novo follows Sanofi, Lilly with insulin price cut in US which offered a 50% cheaper version of its Humalog (insulin lispro) the following month.

The fight for affordable insulin

The fight for affordable insulin The price of Humalog, more commonly used by type 1 patients, also saw its price rise 585% from $35 to $234 between 2001 and 2015. ... Lilly’s authorised generic. One company, Eli Lilly, has responded to the pleas for more affordable insulins, and

1 2 3 4 5 6 7 8 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...